Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
7,318 total articles
Ondas has pivoted from niche commercial drones into a nascent defense platform through acquisitions (World View, BIRD), partnerships (Palantir, Heidelberg) and a sizable cash injection. Management now guides to at least $375M in 2026 revenue after a Q4 2025 quarter of $30.1M (up 629% YoY). The market cap is ~$4.08B; the stock is volatile and techni…
Kinsale (KNSL) has been marked down sharply over the last week, taking the stock back near its 52-week low despite strong profitability, low leverage, and nearly $1.0B in free cash flow. The pullback looks more like sentiment and volatility around insurance cyclicality than a fundamental reset. This trade idea buys the dip with a clearly defined st…
Aurinia has the commercial asset Lupkynis, improving fundamentals (free cash flow of $135.4M, EPS $2.16), low debt and a market cap near $1.9B. With fresh leadership and continued guideline support for calcineurin-based regimens, the stock offers an asymmetric risk/reward in the mid-term. Proposed trade: enter $14.20, stop $12.50, target $17.00 ove…
Brown-Forman (BF.B) is trading around $27.24 after reports of a proposed $60 billion all-stock merger with Pernod Ricard. The combination would create scale, portfolio diversification and distribution leverage that could materially improve Brown-Forman's pricing power and margin profile. This trade idea outlines a long entry at $27.24 with a protec…
Crack spreads have widened as WTI hovers near $99 and refined products remain tight. That dynamic should lift Valero's earnings power even if crude stays elevated. I upgrade Valero to a buy for a position trade, with a defined entry at $180.00, stop at $150.00 and a target of $220.00 over a 180 trading-day horizon.
Meta is trading off sharply after fresh legal developments that could cut against Section 230 protections. The company still posts strong cash generation and margins, but rising regulatory/legal risk plus weak technicals create a tactical short setup over the next 45 trading days. Entry at $526.15, stop at $585.00, target $460.00.
Nvidia is down from recent highs but still shows strong fundamentals: a $4.12 trillion market cap, $96.7B in free cash flow, 76% return on equity and modest net leverage. Technicals look oversold-but-not-broken (RSI ~36) and short interest is meaningful but manageable. This trade targets a mid-term rebound into the $190s as investors reprice growth…
Maze Therapeutics appears to be continuing clinical development of MZE-829 despite a sizable share-price retreat. For traders willing to accept clinical binary risk, a structured long with a defined stop offers asymmetric upside if upcoming milestones validate the molecule's profile. This trade idea lays out an entry at $3.00, a protective stop at …
TotalEnergies is trading near a 52-week high but still offers a compelling risk-reward for investors focused on energy transition winners that finance clean investments from strong cash flow. With a $196.7B market cap, a 4.0% yield, and clear redeployment into LNG and recycling, a long position calibrated for a 180-trading-day horizon offers upside…
AbbVie combines a 3.1%+ yield with accelerating immunology growth from Skyrizi and Rinvoq, free cash flow strength, and a valuation gap that looks bridgeable if execution continues. We initiate a long trade with a $211.90 entry, $195 stop and $250 target over the next 180 trading days while watching near-term catalysts including the 04/15/2026 ex-d…
BKV Corporation combines upstream gas production, midstream processing, power generation and carbon capture in a compact footprint. With a market cap near $3.23B, modest leverage and improving production, BKV is positioned to sell the kinds of dispatchable, lower-carbon power that data centers increasingly demand. We like a tactical long over the n…
Draganfly just secured a $50M lifeline, yet growth must accelerate to justify a $107M market cap. This trade idea argues for a speculative long: management has cash to invest in product and sales, defense/public-safety tailwinds exist, and the stock is technically oversold. But execution risk is high. Enter $4.58, stop $3.50, target $7.00, horizon …
Circle (CRCL) has been oversold on headlines around proposed stablecoin rules. The company’s core product - USDC and its payment/treasury rails - remains mission-critical for crypto markets and enterprise adoption. This trade idea outlines a mid-term buy with a clear entry, stop and target that captures a likely relief rally when the regulatory fog…
Nvidia’s recent pullback is a valuation reset, not a business breakdown. With $96.7B in annual free cash flow, a still-robust P/E near 35x, and new Rubin data-center chips on the horizon, this correction presents a defined-risk entry for a mid-term swing trade. Technical momentum is weak today, but balance-sheet strength, expanding margins and the …
Realty Income (O) faces headline risk from higher rates, but its diversified triple-net portfolio, long leases and built-in escalators make a recession-driven collapse unlikely. This upgrade lays out a pragmatic entry at $60.00, a stop at $55.00 and a primary target of $70.00 over a mid-term horizon while acknowledging balance-sheet and macro risks…
Meta's stock has been sold aggressively into a broader tech swoon, dragging its price-to-cash-flow into low double digits and RSI into deep-oversold territory. Backed by strong cash generation, high ROE, and a new chip partnership that positions Meta inside the AI infrastructure race, this is a tactical long trade sized for a mid-term rebound while…
Lumentum's products power the data center 'nervous system' and recent strategic endorsements (including a $2B partner push) plus S&P inclusion have re-rated the stock. The business shows rapid top-line growth and improving profitability, but multiples are rich and execution and macro risks remain. This is a tactical long for active traders looking …
Garrett Motion (GTX) combines durable free cash flow, improving leverage and exposure to turbo and electric powertrain growth. Q4 momentum and a conservative FY26 outlook create a tactical entry opportunity. We recommend a long trade at $18.31 with a $24.45 target and $15.75 stop for a 180-trading-day horizon.
Nebius just locked down massive capacity deals with hyperscalers and has a backlog that could dwarf its current market cap. This trade idea lays out an entry at $104.51, a $150 target and a $92 stop, with a 45-trading-day horizon to capture contract monetization, rising utilization and accelerating ARR.
Perma-Fix (PESI) has a credible path to outsized H2 2026 revenue and margin improvement driven by nuclear waste volumes, recent pilot success on PFAS destruction, and new government contract access. The balance sheet is manageable, and the stock sits near an oversold technical footprint with short interest elevated - set up a disciplined long with …
First BanCorp (FBP) looks oversold on headlines and positioning risk, but the bank's underlying metrics - low leverage, double-digit ROE, healthy free cash flow and a 3.5% yield - argue against an outright downgrade trade. This is a mid-term swing long with a clear entry, stop and target and a cautious risk plan if macro or asset-quality data deter…
Alphabet’s new AI compression research caused a knee-jerk pullback in memory names, but Sandisk’s fundamentals and industry dynamics suggest the company will continue to capture AI-driven storage demand. This trade idea lays out a mid-term long with a clean entry, stop, and target based on current valuation, cash flow and balance-sheet strength.
Medtronic shares have pulled back into an attractive entry after a period of consolidation. The business generates strong free cash flow ($5.41B last reported), carries a modest leverage profile (debt/equity ~0.57), and yields roughly 3.2% — a combination that supports a buy-on-dip trade while the company executes accretive tuck-ins and rolls out n…
Celestica has rallied into 2026 on AI-driven demand and a visible partnership with AMD. Fundamentals - including $458M of free cash flow, EPS of $7.24, and a healthy balance sheet - support further upside. This trade idea lays out an entry at $275.55, a $320 target and a $260 stop, with a mid-term horizon (45 trading days) and defined risk controls…
Pfizer offers a rare combination in big pharma today: a sub-16x P/E, a 6%-plus yield, strong free cash flow and an improving technical backdrop. I outline an actionable long trade with entry, stop and target, explain the fundamental drivers and catalysts likely to re-rate the stock, and flag the risks that could derail the thesis.
